Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gabapentin extended release - Alvogen

Next Previous
Drug Profile

Gabapentin extended release - Alvogen

Alternative Names: DM-1796; DM-5689; Gabapentin ER; Gabapentin GR; Gralise; Sefelsa; Serada

Latest Information Update: 22 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Depomed; Elan Corporation
  • Developer Assertio Therapeutics
  • Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Gabapentinoids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postherpetic neuralgia
  • Discontinued Diabetic neuropathies; Hot flashes

Most Recent Events

  • 16 Jun 2026 Assertio Therapeutics has been acquired by Zydus Lifesciences
  • 10 Jan 2020 Alvogen acquires Gabapentin extended release from Assertio Therapeutics
  • 12 Dec 2019 Alvogen is expected to complete acquisition of gabapentin extended release in early January 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top